Overview

Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes

Status:
Active, not recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

The investigators aimed to compare efficacy and safety of IGlarLixi and insulin glargine plus dulaglutide as intensification from basal insulin with metformin, in the absence of head-to-head trials.

Phase:

Phase 4

Details

Lead Sponsor:

Chungbuk National University Hospital

Treatments:

Dulaglutide
Insulin Glargine